Teaming up with partners like United Airlines ( ), the move sparked visions of urban skies buzzing with Archer's Midnight aircraft, slashing commute times and emissions. Shares surged over 6% on the news, hitting fresh highs. But the cheering was premature. The program offers a framework for pre-certification tests, yet lacks firm timelines, funding details, or guaranteed slots - it's more roadmap than runway and Archer wasn't a confirmed participant.
Shares of Tylenol maker Kenvue bounced back sharply at the opening bell Tuesday, a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines, and autism. "Don't take Tylenol," Trump instructed pregnant women around a dozen times during the White House news conference Monday, also urging mothers not to give their infants the drug, known by the generic name acetaminophen in the U.S. or paracetamol in most other countries.
Conservative investors might prefer to own shares of traditional insurance companies like Allstate ( NYSE:ALL) and Progressive ( NYSE:PGR), and that's fine. However, if you're more adventurous, you might choose to look into modern disrupters like Lemonade ( NYSE:LMND), Trupanion ( NASDAQ:TRUP), Hippo ( NYSE:HIPO), and the subject of today's analysis, Root, Inc. ( NASDAQ:ROOT). There are risks to investing in high-tech insurance plays, but the potential rewards could be substantial.